Slow Capital Inc. Sells 3,415 Shares of BioNTech SE Sponsored ADR $BNTX

Slow Capital Inc. cut its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 7.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,346 shares of the company’s stock after selling 3,415 shares during the period. Slow Capital Inc.’s holdings in BioNTech were worth $4,828,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. Baader Bank Aktiengesellschaft boosted its holdings in shares of BioNTech by 6.3% during the 2nd quarter. Baader Bank Aktiengesellschaft now owns 151,862 shares of the company’s stock valued at $16,032,000 after acquiring an additional 9,040 shares during the last quarter. Swedbank AB purchased a new stake in BioNTech in the first quarter worth approximately $3,415,000. Millennium Management LLC grew its position in BioNTech by 252.5% in the 1st quarter. Millennium Management LLC now owns 544,970 shares of the company’s stock worth $49,625,000 after purchasing an additional 390,360 shares during the period. OneDigital Investment Advisors LLC purchased a new stake in BioNTech during the 1st quarter valued at $288,000. Finally, Wealth Enhancement Advisory Services LLC bought a new position in shares of BioNTech during the 4th quarter valued at $238,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on BNTX. HC Wainwright reaffirmed a “buy” rating and issued a $136.00 price objective on shares of BioNTech in a report on Monday, September 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioNTech in a research report on Saturday, September 27th. JPMorgan Chase & Co. raised their price objective on shares of BioNTech from $116.00 to $121.00 and gave the stock a “neutral” rating in a report on Monday, September 22nd. Morgan Stanley increased their price target on shares of BioNTech from $132.00 to $133.00 and gave the stock an “overweight” rating in a research report on Thursday, July 10th. Finally, Bank of America lifted their price target on shares of BioNTech from $126.00 to $134.00 and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Ten analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $134.46.

BioNTech Trading Down 0.3%

Shares of BNTX stock opened at $105.16 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.48 and a current ratio of 8.61. The stock has a fifty day simple moving average of $104.83 and a two-hundred day simple moving average of $103.42. The firm has a market capitalization of $25.28 billion, a PE ratio of -65.72 and a beta of 1.45. BioNTech SE Sponsored ADR has a 52-week low of $81.20 and a 52-week high of $129.27.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.19). The business had revenue of $306.46 million during the quarter, compared to the consensus estimate of $161.26 million. BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The business’s revenue was up 102.6% on a year-over-year basis. During the same period last year, the company earned ($3.36) EPS. BioNTech has set its FY 2025 guidance at EPS. On average, analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.